A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 14 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2018 Planned number of patients changed from 58 to 59.
- 16 May 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.